Skip to content
Medical Health Aged Care

DEXIS Attends ADF, Showcases Award-Winning Solutions

DEXIS 4 mins read

QUAKERTOWN, PA / ACCESSWIRE / November 28, 2024 / The latest AI-powered launches from DEXIS enhance diagnostics and patient care. At ADF, DEXIS showcased its innovative product line, including the new intraoral scanners and imaging products. The conference took place November 26-30 at the Palais des Congrès de Paris in Porte Maillot, France. The company's comprehensive range of award-winning solutions covers a complete digital diagnostic workflow, from intraoral scanning and implant planning to sensors, CBCT, and imaging software. With an expanded portfolio and ecosystem, DEXIS Solutions is designed to accelerate workflows, increase productivity, and improve the patient experience.

"Our technology makes it easy to organize information and execute treatments, which is at the core of what clinicians expect from us," said DEXIS President, Robert Befidi. "We are connecting and standardizing the implant workflow while also constantly evaluating our efforts to ensure we provide deeper patient insights and flexible, intuitive solutions that reduce complexity. The latest three launches are a good example of our focus on continuous innovation across the ecosystem to deliver diagnostic confidence, productivity, and smart simplicity."

For many dental professionals, the ADF was the first opportunity to experience the brand new DEXIS ORTHOPANTOMOGRAPH™ OP 3D™ EX and its innovative features that offer expanded 3D diagnostic possibilities. DEXIS solution experts were on hand to provide live demonstrations of key features, including:

  • Tailored images to your diagnostic needs with 66 customizable field of view, from 5 (H) x 5(ø) cm to 10(H) x 15(ø) cm*

  • User friendly 3D acquisition process based on clinical parameters to define and position the field of view

  • Capture high-clarity images while reducing the likelihood for errors through the accuracy and continuity of single-pass capture

  • Solutions to optimize each acquisition to decrease x-ray dose and meet ALARA principle

  • Seamless integration with award-winning AI-powered DTX StudioTM Clinic software & treatment offering expansion

*10 x 15 cm optional field of view size

"The new OP 3D™ EX has significantly improved my workflow. The image quality is excellent, the DTX Studio™ Clinic software is easy to use and the image elaboration very precise, allowing me to make quick and accurate diagnoses. With this device, I can work more efficiently and with greater confidence," says Dr. Massimo Saratti, Switzerland.

The ADF will be an opportunity for dental professionals to discover, among other things, the flagship product of the DEXIS IOS solutions range: the DEXIS IS 3800W wireless scanner, which is aimed at both practitioners who are new to intraoral scanning and experienced users who want more freedom.

The new intraoral scanning software update offers scan quality and usability improvements as well as clear visualizations of progressive dental issues over time, through a new tool called Oral Compare. Additionally, the software's new integration with SmileFy allows for the ability to simulate treatment outcomes chairside, giving patients further confidence in proposed treatment plans.

The IS 3800W will increase dental practitioners' efficiency and take their practice to the next level. It offers many benefits, including:

  • Ultra-lightweight (240g) and compact wireless intraoral scanner

  • Ultra-fast impression capture demonstrated in 25 seconds for one arch**

  • Up to one hour of continuous impression capture on a single battery charge

  • No licensing, no additional fees

  • 2-year manufacturer warranty, with the option to extend up to 5 years

To learn more about DEXIS solutions, visit: https://to.dexis.com/fr-fr/adf-2024

** In vitro testing performed on a plaster model.

About DEXIS

DEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging (such as Gendex™, SOREDEX™, i-CAT™, and Instrumentarium™), intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, visit our page www.dexis.com/fr-fr.

About Envista Holdings Corporation

Envista is a globally recognized family of more than 30 trusted dental brands, including DEXIS, Nobel Biocare, Ormco and Kerr, united by a shared purpose: to partner with dental professionals to improve the lives of patients. Envista helps its customers deliver the best possible patient care through innovative dental supplies, solutions, technologies and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics and digital imaging technologies, covers a wide range of dentists' clinical needs for the diagnosis, treatment and prevention of dental diseases, as well as for the improvement of smile aesthetics. Through the proven methodology of the Envista Business System (EBS), an experienced management team and a strong culture focused on continuous improvement, commitment to innovation and customer satisfaction, Envista has the ability to meet the global needs of dental professionals. Envista is one of the world's largest dental products companies, with significant market positions in some of the most attractive segments of the dental industry. For more information, visit www.envistaco.com.

.

Source: DEXIS

More from this category

  • Community, Medical Health Aged Care
  • 16/02/2026
  • 06:00
Hearts4heart

Charity launches national movement to spotlight Australia’s dangerously ‘SLOW’ response to heart valve disease

MEDIA RELEASE Monday, 16 February 2026: Australia’s response to heart valve disease is moving dangerously slowly, putting hundreds of thousands of lives at risk. To help change that, leading heart charity, Hearts4heart is launching the nation’s first ‘SLOW Symptoms’ campaign during Heart Valve Disease Awareness Week (16–22 February 2026). In 2021, an estimated 600,000 Australians were living with diagnosed heart valve disease, with a further 254,000 people unaware they had the condition, meaning an estimated 850,000 Australians may already be affected.1,2 Australian and global heart health advocates now warn heart valve disease is “the next cardiac epidemic”, driven by an…

  • General News, Medical Health Aged Care
  • 16/02/2026
  • 06:00
CSL Seqirus

neffy®, adrenaline nasal spray, now approved to treat anaphylaxis in Australia

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been approved for use in Australia for the emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over.1 Anaphylaxis occurs after exposure to an allergen, such as food, medications and insect bites and stings, and can be life threatening if not immediately treated with adrenaline.3 Adrenaline rapidly reverses the effects of the condition by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure.3 Anaphylaxis…

  • Medical Health Aged Care
  • 16/02/2026
  • 06:00
Vertex

Vertex Announces Reimbursement for ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) in Australia, a new once-daily next-in-class Treatment for People with Cystic Fibrosis

ALYFTREK®is now reimbursed for Australians with cystic fibrosis (CF) aged 6 years and older with at least one responsive mutation – Approximately 3,200 Australians living with CF are now able to access this next-in-class treatment[i] – SYDNEY, Sunday 15th February 2026 – Vertex Pharmaceuticals today announced that as of 1 February 2026, ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) will be funded on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people aged 6 years and older with cystic fibrosis (CF) and who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is considered responsive, based on clinical…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.